Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

EOS (Ethical Oncology Science)

Request full access

Biopharmaceutical company committed to the development of novel medicines for the treatment of cancer.

Milan, ItalyFounded 2006Biotech & Life Sciences

About EOS (Ethical Oncology Science)

Ethical Oncology Science (EOS) S.p.A. operated as a private Italian biopharmaceutical firm focused on developing targeted cancer therapies. Founded in June 2006, the Milan-based company was established by a team of experienced bio-entrepreneurs: Silvano Spinelli, who served as CEO and Chairman; Gabriella Camboni, the Chief Operating Officer; and Ennio Cavalletti, who was the VP of Operations. The founding team was composed of seasoned professionals with extensive backgrounds in translational medicine and a successful track record in oncology drug development.

The company's core asset was lucitanib, an oral drug candidate. EOS held the exclusive global development and commercialization rights for lucitanib, excluding China, which it acquired from Advenchen Laboratories LLC. The business strategy centered on advancing this asset through clinical trials and forming strategic partnerships to maximize its market reach. In 2012, EOS executed a significant licensing agreement, sublicensing the European and rest-of-world rights (excluding China) for lucitanib to the French pharmaceutical company Les Laboratoires Servier. This move secured a collaborator for development and future commercialization in those territories.

Lucitanib is a dual-selective inhibitor that targets the tyrosine kinase activity of fibroblast growth factor (FGF) receptors 1 and 2, as well as vascular endothelial growth factor (VEGF) receptors 1 through 3. By simultaneously inhibiting these two validated pathways involved in tumor growth and angiogenesis (the formation of new blood vessels), the drug was positioned to treat various cancers. The initial clinical development program focused on patients with FGF-aberrant breast cancer, a group representing about 25% of breast cancer cases. Clinical trials, which began in Europe in July 2010, showed objective responses in this patient group and also in patients with tumors sensitive to angiogenesis inhibitors, such as renal cell and thyroid cancer.

The company's journey culminated in November 2013 when it was acquired by Clovis Oncology, a US-based biopharmaceutical company. The transaction involved an upfront payment of $200 million, comprised of stock and cash, with substantial additional milestone payments contingent on regulatory approvals and sales targets. Following the acquisition, Clovis Oncology gained the U.S. and Japan rights to lucitanib and continued its development in collaboration with Servier.

Source: Dealroom company data

At a glance

Status
Acquired
Open positions
None listed
Dealroom signal
52.2/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Developer Tools, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITION✓Exit Nov 2013 $200M $200M Clovis Oncology —
SERIES A✓Equity / VC Jun 2009 $17M $68M Aescap · Sofinnova Partners —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

EOS (Ethical Oncology Science) website traffic

Latest recorded traffic for EOS (Ethical Oncology Science) is 0 monthly website visits.

Latest monthly visits0
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

EOS (Ethical Oncology Science) in the Milan ecosystem

Live from Dealroom

The EOS (Ethical Oncology Science) office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

Other known investors2 additional known investors

Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇮🇹 Italy · Milan HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about EOS (Ethical Oncology Science) on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See EOS (Ethical Oncology Science)’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.